Beyond Air preannounces record quarterly revenue and reaffirms CY guidance

What happened

Beyond Air preannounced preliminary revenue of approximately $2.3 million for the quarter ended September 30, 2026, representing a 30% sequential increase and 27% year-over-year growth, and reaffirmed revenue guidance of $8 million for CY2026 and $16–18 million for CY2027. This follows a period of execution strain, marked by a prior cut in fiscal 2026 guidance to $8–10 million, flat sequential revenue in the September 2025 quarter, and explicit going-concern warnings amid negative gross margins and heavy reliance on high-cost debt and a dilutive equity line. The company attributed the record quarterly result to continued adoption of its first-generation LungFit PH system, while noting that the second-generation system remains under FDA review, with no update on approval timing. Despite the improved revenue trajectory, Beyond Air's financial position remains fragile: as of the last reported quarter (September 2025), cash and securities totaled $10.7 million against $10.1 million in long-term debt and additional insider liabilities, and quarterly cash burn was approximately $4.7 million. The preannouncement provides evidence that commercialization is progressing, but it does not yet confirm that gross margins have turned positive or that the company can navigate its financing needs without further dilution.

Implication

Investors should view the preliminary $2.3 million quarter as validation of continued LungFit PH adoption, but the 27% year-over-year growth remains off a very small base and does not yet demonstrate the scale needed to absorb fixed costs and royalty obligations. The reaffirmation of a lower CY2026 revenue target of $8 million, versus the prior FY26 range of $8–10 million, suggests management is guiding conservatively, but growing to $16–18 million in CY2027 implies a step-change that hinges on Gen II approval and faster hospital conversions. Until gross margin turns positive and cash burn declines meaningfully, the company will likely continue to rely on its $20 million equity line and high-cost debt, creating a significant overhang on the equity. The pending FDA decision on second-generation LungFit PH remains a critical binary catalyst: approval could accelerate adoption and improve unit economics, while delay or rejection would force continued reliance on the less efficient first-generation system. Given these factors, we maintain a WAIT stance, preferring to see at least another quarter of revenue growth with improving gross margin and evidence of controlled dilution before considering a more constructive view.

Thesis delta

The preliminary revenue preannouncement provides a modest positive data point that slightly increases confidence in the base case, but it does not alter the fundamental thesis of a WAIT. The sequential acceleration to $2.3 million and reaffirmed CY2027 guidance of $16–18 million suggest the growth trajectory is intact, yet the key risks—negative gross margins, dilutive financing, and Gen II approval uncertainty—remain unresolved. Therefore, we keep the rating unchanged at WAIT, with no change to conviction.